| Literature DB >> 7921922 |
S C Gulati1, R Gopal, J B Prowda, S Spanik, M Jain, A Gopal.
Abstract
Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin, etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoietic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim, etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.Entities:
Mesh:
Substances:
Year: 1994 PMID: 7921922 DOI: 10.1007/bf02990084
Source DB: PubMed Journal: Med Oncol ISSN: 1357-0560 Impact factor: 3.064